Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial source : Www.inovio.com save search
INOVIO Receives FDA Feedback that Data from Completed Phase 1/2 Trial of INO-3107 Can Be Used to Submit a BLA Under Accelerated Approval Program
Published: 2023-10-10 (Crawled : 12:30) - inovio.com
INO | $10.1 -2.6% -2.67% 250K
|
Health Technology
|
| O: 13.73%
H: 45.31%
C: 23.98%
ino-3107 fda approval program trial
INOVIO Collaborates with GuardRX and Geneva University Hospitals for Heterologous Booster Clinical Trial of its Ebola DNA Vaccine Candidate, INO-4201
Published: 2021-11-16 (Crawled : 13:30) - inovio.com
INO | $10.1 -2.6% -2.67% 250K
|
Health Technology
|
| O: -2.88%
H: 0.0%
C: 0.0%
vaccine trial
INOVIO Further Expands INNOVATE Phase 3 Trial for COVID-19 DNA Vaccine Candidate INO-4800 With Regulatory Authorization from India
Published: 2021-11-03 (Crawled : 12:15) - inovio.com
INO | $10.1 -2.6% -2.67% 250K
|
Health Technology
|
| O: 2.35%
H: 0.81%
C: 0.67%
covid india vaccine phase 3 trial ino-4800
INOVIO Receives Regulatory Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800, in Mexico
Published: 2021-09-22 (Crawled : 12:15) - inovio.com
INO | $10.1 -2.6% -2.67% 250K
|
Health Technology
|
| O: 0.25%
H: 0.76%
C: -1.14%
covid vaccine phase 3 trial authorized ino-4800
INOVIO Receives Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800
Published: 2021-08-26 (Crawled : 12:15) - inovio.com
INO | $10.1 -2.6% -2.67% 250K
|
Health Technology
|
| O: 4.86%
H: 8.36%
C: -1.69%
covid vaccine phase 3 trial authorized ino-4800
INOVIO and Advaccine Receive Regulatory Allowance for Two Heterologous Prime-Boost Clinical Trials in China Using INO-4800, INOVIO’s COVID-19 DNA Vaccine Candidate
Published: 2021-08-09 (Crawled : 12:00) - inovio.com
INO | $10.1 -2.6% -2.67% 250K
|
Health Technology
|
| O: -1.16%
H: 8.32%
C: 4.77%
covid clinical trials china vaccine trial ino-4800 primec
INOVIO Expands Partnership with Advaccine to Conduct Global Phase 3 Efficacy Trial of COVID-19 DNA Vaccine Candidate, INO-4800
Published: 2021-06-08 (Crawled : 12:15) - inovio.com
INO | $10.1 -2.6% -2.67% 250K
|
Health Technology
|
| O: 2.49%
H: 0.46%
C: -0.69%
covid partnership vaccine phase 3 trial ino-4800
INOVIO Planning for ex-US Global Phase 3 Trial for INO-4800
Published: 2021-04-23 (Crawled : 12:15) - inovio.com
INO | $10.1 -2.6% -2.67% 250K
|
Health Technology
|
| O: -27.71%
H: 6.67%
C: 3.79%
phase 3 trial ino-4800
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.